Lirafugratinib Hydrochloride

Clicks: 2
ID: 338693
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #249 of 255 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 255 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AHFS CLASS: 10:00 Antineoplastics Brand: Lyrfigtu® Lirafugratinib is a small molecule kinase inhibitor that inhibits FGFR2. Lirafugratinib hydrochloride is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement. Lirafugratinib hydrochloride is available in the following dosage form(s) and strength(s): Capsules: 20 mg and 30 mg of lirafugratinib ... None. Lirafugratinib can cause retinal pigment epithelial detachment (RPED), which may cause symptoms such as blurred vision. Among 385 patients who received lirafugratinib and underwent ophthalmologic monitoring, including optical coherence tomography (OCT), RPED occurred in 31% of patients with 12% patients having Grade 2 and 1.8% Grade 3. The median time to onset of RPED was 57 days (range 4 to 221). RPED led to dose interruption of lirafugratinib in 15% of patients, and dose reduction in 10% of patients. Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 13 months, and every 4 months thereafter. For onset of visual symptoms, obtain ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of lirafugratinib. Withhold or reduce the dose of lirafugratinib as recommended.
Reference Key
openalex_W7225262605 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag355
URL
https://doi.org/10.1093/ajhp/zxag355
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.